Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

BACKGROUND: We compared the efficacy of the antiviral agent, remdesivir, versus standard-of-care treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a phase 3 remdesivir trial and a retrospective cohort of patients with severe COVID-19 treated with standard of care. M...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Infect Dis
Main Authors: Olender, Susan A, Perez, Katherine K, Go, Alan S, Balani, Bindu, Price-Haywood, Eboni G, Shah, Nirav S, Wang, Su, Walunas, Theresa L, Swaminathan, Shobha, Slim, Jihad, Chin, BumSik, De Wit, Stéphane, Ali, Shamim M, Soriano Viladomiu, Alex, Robinson, Philip, Gottlieb, Robert L, Tsang, Tak Yin Owen, Lee, I-Heng, Hu, Hao, Haubrich, Richard H, Chokkalingam, Anand P, Lin, Lanjia, Zhong, Lijie, Bekele, B Nebiyou, Mera-Giler, Robertino, Phulpin, Chloé, Edgar, Holly, Gallant, Joel, Diaz-Cuervo, Helena, Smith, Lindsey E, Osinusi, Anu O, Brainard, Diana M, Bernardino, Jose I
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Online Only Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7454434/
https://ncbi.nlm.nih.gov/pubmed/32706859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciaa1041
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados